Cited by 285Systemic Lupus Erythematosus ResearchVenous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis

Wahl, DG, Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., Thibaut, G.·1997·Lupus

DOI 10.1177/096120339700600510

Open this paper in CoChat — free account

Abstract

Objective: To describe the relative risk for venous thrombosis (VT) associated with antiphos pholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Design: Systematic review and meta-analysis of 26 articles that examined the association between aPL and VT in SLE. Setting: Mostly secondary and tertiary referral centres. Patients: 2249 patients with SLE, 1120 tested for LA (lupus anticoagulant) and 1563 tested for aCL (anticardiolipin antibodies). Main outcome measures: A summary of study characteristics and a critical appraisal of study quality were done. Two statistical combinations of 18 primary studies that examined the association of VT and LA and of 14 studies that examined the association of VT and aCL were performed to estimate the risk for VT associated with aPL. Results: The odds ratios of the risk of VT related to the LA summarized from 18 studies were 5.61 [95% CI; 3.80-8.27] overall, 6.32 [CI; 3.71-10.78] for deep venous thrombosis and pulmonary embolism, 11.6 [3.65--36.91] for recurrent venous thrombosis after the first event. The odds ratios of the risk of VT related to aCL summarized from 14 studies were 2.17 [95% CI; 1.51-3.11] overall, 2.50 [CI; 1.51-4.14] for deep venous thrombosis and pulmonary embolism, 3.91 [1.14- 13.38] for recurrent venous thrombosis after the first event. Conclusions: Patients with SLE and LA are at approximately six times greater risk for VT than patients without LA, whereas patients with SLE and aCL are approximately two times greater risk for VT than patients without aCL. We have identified important methodologic limitations and differences in study characteristics. Other risk factors for VT have not been thoroughly evaluated in these studies. Further studies are needed that provide an accurate estimate of the absolute risk for aPL related VT.

Integrity signals

Registry

Crossref · 10.1177/096120339700600510

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Statistical Methods in Medical Research.
Armitage, P. (1972) · Biometrics · doi:10.2307/2556182 · Cited by 5,383
Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635
Clinical Recommendations Using Levels of Evidence for Antithrombotic Agents
Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L., & Goldberg, R. J. (1995) · CHEST Journal · doi:10.1378/chest.108.4_supplement.227s · Cited by 275
Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus
Horbach, D. A., van Oort, E., Donders, R. C. J. M., Derksen, R. H. W. M., & de Groot, P. G. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650686 · Cited by 246
Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage.
Anglés‐Cano, E., Sultan, Y., & Clauvel, J. (1979) · PubMed · Cited by 219
Thrombosis in Systemic Lupus Erythematosus
Glueck, H. I. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360080059007 · Cited by 192
Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus
KALUNIAN, K. C., Middlekauff, H. R., Sayre, J. A., Ando, D. G., Mangotich, M., Hahn, B. H., & Peter, J. B. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80229-8 · Cited by 150
Anticardiolipin antibodies in patients with systemic lupus erythematosus
Sturfelt, G. K., Nived, O., Norberg, R., Thorstensson, R., & Krook, K. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300404 · Cited by 124
SLE: a Rheumatological View. Analysis of the Clinical Features, Serology and Immunogenetics of 100 SLE Patients During Long-term Follow-up
Worrall, J. G., SNAITH, M. L., Batchelor, J. R., et al. (1990) · QJM · doi:10.1093/oxfordjournals.qjmed.a068440 · Cited by 114
Platelet Function and Coagulation Profile in Lupus Erythematosus
Regan, M. G., LACKNER, H., & KARPATKIN, S. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-462 · Cited by 109

Show all 29 references

Research works printed but not linked: 9

Chalmers I, 1995, Systematic Reviews
Bowie Ejw, 1963, Clin Med, 62, 416
Angles-Cano E., 1979, J Lab Clin Med, 94, 312
Gladman DD, 1983, Q J Med, 52, 424
Petri M., 1987, Arch Intern Med, 106, 524
Rowell NR, 1989, Acta Derm Venereol (Stockh), 69, 111
Worrall JG, 1990, Q J Med, 74, 319
Wong KL, 1991, J Rheumatol, 18, 1187
Metz D., 1994, Presse Med, 23, 1797

Sorted by citations

Items 101–200 of 282

Severe Pulmonary Hypertension Associated with Primary Sjoegren's Syndrome
Nakagawa, N., Osanai, S., Ide, H., et al. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.1248 · Cited by 34
Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?
Bardin, N., Alessi, M., Dignat‐George, F., Juhan-Vague, I., Sampol, J., Harle, J. ‐., & Sanmarco, M. (2007) · Immunobiology · doi:10.1016/j.imbio.2007.02.001 · Cited by 34
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: A prospective cohort of 2736 women
Chauleur, C., Quenet, S., Varlet, M.-N., SEFFERT, P., Laporte, S., Decousus, H., & Mismetti, P. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.12.020 · Cited by 33
Atherosclerosis in autoimmune diseases
Matsuura, E., Kobayashi, K., & Lopez, L. R. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0009-1 · Cited by 32
“Antiphospholipid antibodies increase the risk of thrombosis by at least twofold when present in the context of an autoimmune disease [ 24 ].”
Background
Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus
Ruiz, D., Oates, J. C., & Kamen, D. L. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.07.007 · Cited by 31
Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus
Frijns, C. J. M., Derksen, R. H. W. M., Groot, P., et al. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01520.x · Cited by 28
Atteinte respiratoire au cours du lupus érythémateux systémique
Carmier, D., Marchand-Adam, S., Diot, P., et al. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)75093-9 · Cited by 27
Contraception in autoimmune diseases
Benagiano, G., Benagiano, M., Bianchi, P., D’Elios, M. M., & Brosens, I. A. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.05.003 · Cited by 26
Risk of Vascular access Thrombosis in Patients with Systemic Lupus Erythematosus on Hemodialysis
Shafi, S., & Gupta, M. (2007) · The Journal of Vascular Access · doi:10.1177/112972980700800207 · Cited by 26
“SLE patients with lupus anticoagulant or anticardiolipin antibody appear to be at higher risk for developing venous thrombosis (20).”
Background
Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis?
Bertolaccini, M. L., & Hughes, G. R. V. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.001 · Cited by 26
Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus
Becker, Y. L. C., Gagné, J., Julien, A., Lévesque, T., Allaeys, I., Gougeard, N., Rubio, V., Boisvert, F., Jean, D., Wagner, E., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42082 · Cited by 26
Risk of venous thromboembolism and oral contraceptives
Gompel, A., Carpentier, S., Francès, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08298-3 · Cited by 25
Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.
Musiał, J., Swadźba, J., Motyl, A., & Iwaniec, T. (2003) · PubMed · Cited by 25
Clinical pattern of systemic lupus erythematosus in Western Saudi Arabia
Qari, F. A. (2002) · Saudi Medical Journal · doi:10.15537/1658-3175.1851 · Cited by 24
Loss of antiphospholipid antibody positivity post-thrombosis in SLE
Khawaja, M., Magder, L. S., GOLDMAN, D. W., & Petri, M. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000423 · Cited by 22
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Fonseca, A. G., & D’Cruz, D. P. (2008) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-5-6 · Cited by 23
The association of antibodies to cardiolipin,β2‐glycoprotein I, prothrombin, and oxidized low‐density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus
Koskenmies, S., Vaarala, O., Widén, E., et al. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410005386 · Cited by 21
The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies
Membré, A., Wahl, D. G., Latger‐Cannard, V., Max, J., Lacolley, P. J., Lecompte, T., & Regnault, V. (2008) · Haematologica · doi:10.3324/haematol.12364 · Cited by 21
Self-citation
The Antiphospholipid Syndrome.
Gattorno, M. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.6.349b · Cited by 19
Antiphospholipid Syndrome: General Features
Godfrey, T., & D’Cruz, D. P. (2000) · Springer eBooks · doi:10.1007/978-1-4471-3666-8_2 · Cited by 21
Systemic Lupus Erythematosus-related Lung Disease
Bendstrup, E. M., Lynn, E., & Troldborg, A. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1782653 · Cited by 21
Recent advances in understanding antiphospholipid syndrome
Bertolaccini, M. L., & Sanna, G. (2016) · F1000Research · doi:10.12688/f1000research.9717.1 · Cited by 20
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Öztürk, M. A., Haznedaroğlu, İ. C., Turgut, M., & Göker, H. (2004) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960401000201 · Cited by 19
“LAs are more closely associated with arterial and/or venous thrombosis than ACA antibodies (235,241,253,254).”
Background
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus
Taraborelli, M., Lazzaroni, M. G., Martinazzi, N., et al. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.891 · Cited by 19
Pulmonary Hypertension in Systemic Lupus Erythematosus
Akdoğan, A., Kılıç, L., Doğan, İ., et al. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000037 · Cited by 18
“Patients with SLE with antiphospholipid antibodies had more than 6 times increased risk for developing venous thromboembolism than did patients with SLE without antiphospholipid antibodies.(14) Antiphospholipid antibodies are found in 10% to 20% of CTEPH patients and are reported to be a risk factor for CTEPH.”
Background
Chapter 2 Epidemiology of the Antiphospholipid Syndrome
Mehrani, T., & Petri, M. (2009) · Technical report · doi:10.1016/s1571-5078(08)00402-9 · Cited by 18
“This has also been the finding in the SLE literature [44].”
Result
Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review
Shlebak, A. A. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203077 · Cited by 19
Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis
Sidelmann, J. J., Sjøland, J. A., Gram, J., Bertelsen, V., Mourits‐Andersen, T., Münster, H., Münster, A. B., & Jespersen, J. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601038992 · Cited by 20
Specificity and sensitivity of anti-β2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome
Parkpian, V., Verasertniyom, O., Vanichapuntu, M., et al. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0566-5 · Cited by 17
“Subsequently, a meta-analysis study concluded that LAC is more strongly associated with risk of venous thrombosis than aCL, although both are statistically significant [5].”
Background
Therapeutic Potential of Toleragens in the Management of Antiphospholipid Syndrome
Cockerill, K. A., Iverson, G. M., Jones, D. S., & Linnik, M. D. (2004) · BioDrugs · doi:10.2165/00063030-200418050-00002 · Cited by 18
The Antiphospholipid Syndrome
Park, K. W. (2004) · International Anesthesiology Clinics · doi:10.1097/00004311-200404230-00006 · Cited by 17
Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis
Lopez, L. R., Kobayashi, K., Matsunami, Y., & Matsuura, E. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8096-8 · Cited by 17
“Patients with systemic autoimmune diseases such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) develop lifethreatening complications of both the venous and arterial vasculatures [1, 2].”
Background
Thromboprophylaxis and obstetric management of the antiphospholipid syndrome
Espinosa, G., & Cervera, R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902772302 · Cited by 16
“Specifically, this major risk is present both in patients with SLE [30] and primary APS [31].”
BackgroundInfluential
Beyond Skin Deep: Thoracic Manifestations of Systemic Disorders Affecting the Skin
Kanne, J. P., Yandow, D. R., Haemel, A. K., et al. (2011) · Radiographics · doi:10.1148/rg.316115516 · Cited by 17
“CT pulmonary angiography may be warranted in patients with SLE who present with pleuritic chest pain or acute dyspnea, because more than 50% of patients with SLE have antiphospholipid antibodies, an independent risk factor for the development of deep venous thrombosis and pulmonary thromboembolism (56).”
Background
Herzinfarkt und Thrombembolie in der Schwangerschaft
H�rtel, D., Sorges, E., CARLSSON, J., et al. (2003) · Herz · doi:10.1007/s00059-003-2453-4 · Cited by 17
“In der Normalbevölkerung wird das Thromboserisiko bei Vorliegen von Anti-Cardiolipin-Antikörpern auf das Zweifache und bei Lupusantikoagulanzien auf das Fünf- bis Zehnfache erhöht beschrieben [46, 47].”
Background
Classification and Epidemiology of the Antiphospholipid Syndrome
Petri, M. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50004-8 · Cited by 17
An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus
Hisada, R., & Atsumi, T. (2023) · Biomolecules · doi:10.3390/biom13040617 · Cited by 18
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome
Aguirre-del-Pino, R., Monahan, R. C., Huizinga, T. W. J., Eikenboom, J. C. J., & Steup‐Beekman, G. M. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1776910 · Cited by 21
Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis
Tsuruta, Y., Uchida, K., Itabashi, M., Yumura, W., & Nitta, K. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.2363 · Cited by 16
The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus
Venturelli, V., Abrantes, A. M., Rahman, A., & Isenberg, D. A. (2024) · Rheumatology · doi:10.1093/rheumatology/kead618 · Cited by 17
The frequency of anti-β2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease
Hasegawa, E., Caleiro, M., Fuller, R., et al. (2009) · Lupus · doi:10.1177/0961203308101719 · Cited by 15
Effect of menopause hormone therapy on disease progression in systemic lupus erythematosus: A systematic review
Khafagy, A. M., Stewart, K. I., Christianson, M. S., et al. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.03.017 · Cited by 15
Pediatric Systemic Lupus Erythematosus
Weiss, J. E. (2012) · Pediatrics in Review · doi:10.1542/pir.33.2.62 · Cited by 15
Thrombophilia and Pregnancy
Hendrix, P. W., Tinelli, A., Malvası, A., & Paidas, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31377-1_13 · Cited by 15
WHICH ANTIPHOSPHOLIPID ANTIBODY TESTS ARE MOST USEFUL?
Merrill, J. T. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70218-0 · Cited by 15
Contraception for women with systemic lupus erythematosus
Culwell, K. R., & Curtis, K. M. (2012) · Journal of Family Planning and Reproductive Health Care · doi:10.1136/jfprhc-2012-100437 · Cited by 14
Short-form arthritis impact measurement scales 2: Tests of reliability and validity among patients with osteoarthritis
Ren, X. S., Kazis, L., & Meenan, R. F. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)12:3
Accelerated Atheroma in the Antiphospholipid Syndrome
Matsuura, E., Kobayashi, K., Tabuchi, M., & Lopez, L. R. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.006 · Cited by 14
Contraception for adolescents with chronic rheumatic diseases
Lourenço, B., Kozu, K. T., Leal, G. N., Silva, M. F., Fernandes, E. G. C., França, C. M. P., de Souza, F. H. C., & Silva, C. A. (2016) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2016.07.016 · Cited by 13
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen
Mendel, A., Bernatsky, S., Pineau, C. A., St‐Pierre, Y., Hanly, J. G., Urowitz, M. B., Clarke, A. E., Romero‐Díaz, J., Gordon, C., Bae, S., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez014 · Cited by 13
AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update
ACTION, O. B. O. A., Barbhaiya, M., ANDRADE, D. C. O. D., et al. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0611-y · Cited by 12
The Impact of Coagulopathy on Clinical Outcomes following Microsurgical Breast Reconstruction
Liu, F. C., Miller, T. J., Wan, D. C., et al. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000008099 · Cited by 12
Immunopurification of human β2-glycoprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor
Regnault, V., Arvieux, J., Vallar, L., et al. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00209-3 · Cited by 12
Self-citation
The antiphospholipid syndrome
Franchini, M., & Veneri, D. (2005) · Hematology · doi:10.1080/10245330500141309 · Cited by 12
“[28] Wahl DG, Guillemin F, de Maistre E, et al.”
Background
Antiphospholipid Syndrome
Wysokinska, E. M., & Ortel, T. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00020-0 · Cited by 11
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Riancho‐Zarrabeitia, L., Martínez-Taboada, V. M., Rúa‐Figueroa, Í., Sánchez‐Alonso, F., Galindo-Izquierdo, M., Ovalles-Bonilla, J. G., Olivé, A., Vázquez, N. M., Alén, J. C., Almagro, R. M., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/9kxexc · Cited by 9
Systemic Lupus Erythematosus
Petri, M., Aringer, M., Ayoub, I. M., Almaani, S. J., Brunner, H. I., Dall’Era, M., Jiang, M., Furie, R. A., Greco, J. M., Goldblatt, F., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_12 · Cited by 12
Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients
Dima, A., Caraiola, S., Jurcuț, C., Balanescu, A., Balanescu, P. C., Ramba, D., Badea, C. G., Pompilian, V. M., Ionescu, R. A., Băicuş, A., et al. (2015) · Romanian Journal of Internal Medicine · doi:10.1515/rjim-2015-0041 · Cited by 10
“The aCL positivity carries a 2-fold increase of venous thrombosis in SLE patients [22].”
Background
Circulating Endothelial Cells are Associated with Thromboembolic Events in Patients with Antiphospholipid Antibodies
Foret, T., Dufrost, V., Heymonet, M., Risse, J., Faure, G. C., Louis, H., Lagrange, J., Lacolley, P. J., Devreese, K. M. J., Gibot, S., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1926-0453 · Cited by 12
Self-citation
The characteristics of systemic lupus erythematosus. A study in a general hospital
Karadsheh, M. F., Nimri, F. A., Ajlouni, Y., et al. (2000) · Saudi Medical Journal · doi:10.15537/1658-3175.1130 · Cited by 9
The antiphospholipid antibody syndrome
Nimmo, M., & Carter, C. J. (2003) · Clinical and Applied Immunology Reviews · doi:10.1016/s1529-1049(03)00047-3 · Cited by 8
Pursuing the debate on the serologic criteria that define the antiphospholipid syndrome
Wahl, D. G., Thiébaugeorges, O., Regnault, V., Dalloul, A. H., & Lecompte, T. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03009.x · Cited by 9
Self-citation
Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety
Qushmaq, N. A., & Al-Emadi, S. A. (2014) · ISRN Rheumatology · doi:10.1155/2014/348726 · Cited by 8
“Further, the study also revealed that 42% of the examined patients exhibited low-risk rates of thrombosis due to high aPL levels, which indicated lesser benefits from aspirin administration [45, 46].”
Result
Need for additional trials of primary prophylaxis in patients with high‐risk antiphospholipid antibody profiles: Comment on the article by Erkan et al
Wahl, D. G., Lecompte, T., & Bounameaux, H. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23160 · Cited by 8
Self-citation
Thrombophilia and thrombosis in systemic lupus erythematosus: a case-control study
Barcat, D., Guérin, V., Ryman, A., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.10.1016 · Cited by 8
Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
Calcaterra, I. L., Ambrosino, P., Vitelli, N., Lupoli, R., Orsini, R. C., Chiurazzi, M., Maniscalco, M., & Minno, M. N. D. D. (2021) · Biomedicines · doi:10.3390/biomedicines9020122 · Cited by 9
Long-term follow-up of lymphocyte populations and cellular cytokine production in patients with chronic graft-versus-host disease treated with extracorporeal photopheresis.
da Silva, M. G., Neto, L. F., Guimarães, A., et al. (2005) · PubMed · Cited by 8
Management of the antiphospholipid syndrome
Espinosa, G., & Cervera, R. (2010) · Autoimmunity Highlights · doi:10.1007/s13317-010-0004-6 · Cited by 7
“However, a recent prospective study in patients with SLE has demonstrated that LA-positive patients have a greatly increased risk of thrombosis, both at the arterial and venous level.”
BackgroundInfluential
Prevention of Pulmonary and Venous Thromboembolism Post Coronary Artery Bypass Graft Surgery – Literature Review
Jannati, M., & Abdi‐Ardekani, A. (2019) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2018-0345 · Cited by 7
Reproductive Health Care for Female Adolescents Prescribed Mycophenolate at a Children’s Hospital: A 10-Year Retrospective Cohort Study
Al-Husayni, N., Maslyanskaya, S., Rubinstein, T. B., & Coupey, S. M. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.09.052 · Cited by 8
Antiphospholipid (Hughes) Syndrome: An Overview
D’Cruz, D. P. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_2 · Cited by 7
“When recurrent venous events were examined these ratios increased to 11.6 and 3.91, respectively [28] .”
Influential
Lupus anticoagulants in children
Briones, M. A., & Abshire, T. C. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200309000-00009 · Cited by 7
Treatment of Antiphospholipid Syndrome
Espinosa, G., & Cervera, R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10055-5 · Cited by 7
SYSTEMIC LUPUS ERYTHEMATOSUS AND THE LUNG
Lawrence, E. C. (2004) · Elsevier eBooks · doi:10.1016/b978-012433901-9/50036-3 · Cited by 9
Evidence-based treatment of the antiphospholipid syndrome
Wislöff, F., & Crowther, M. A. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.05.006 · Cited by 7
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE
Gómez-Bañuelos, E., Celia, A. I., Trejo‐Zambrano, M. I., Anda, J.-A. R.-D., Paz, M., Chaturvedi, S., Conti, F., Alessandri, C., Tiniakou, E., GOLDMAN, D. W., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.04.015 · Cited by 6
Pattern of disease expression in SLE patients with antiphospholipid antibodies: data from Indian Systemic Lupus Erythematosus Inception cohort (INSPIRE)
Shobha, V., Rajasekhar, L., Manuel, S., Nayana, V., Kavadichanda, C. G., Kounassegarane, D., Mathew, A. J., Gupta, R., Rathi, M., Ghosh, P., et al. (2023) · Rheumatology International · doi:10.1007/s00296-023-05511-2 · Cited by 6
Contracepção para adolescentes com doenças reumáticas crônicas
Lourenço, B., Kozu, K. T., Leal, G. N., Silva, M. F., Fernandes, E. G. C., França, C. M. P., de Souza, F. H. C., & Silva, C. A. (2016) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2016.06.005 · Cited by 6
Antiphospholipid Antibody Positivity and the Clinical Outcomes of Patients with Systemic Lupus Erythematosus
Nam, S. W., Cho, S., Kim, D., Lee, K.-E., Park, D.-J., Lee, S., & Sung, Y. (2018) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2018.25.4.239 · Cited by 7
Coagulation Disorders in Pregnancy
Lockwood, C. J., & Silver, R. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4224-2.50043-0 · Cited by 7
Thromboembolic Disorders
Pettker, C. M., & Lockwood, C. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1935-2.00043-0 · Cited by 6
Increased risk of pulmonary embolism in patients with dermatomyositis/polymyositis, a retrospective cohort study from Israel
Amster, R., Watad, A. E., Shani, U., et al. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109203 · Cited by 5
A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations
Dar, S., Koirala, S., Khan, A., Bellary, M. D., Patel, A. V., Mathew, B., Singh, R., Baigam, N., Razzaq, W., Abdin, Z. U., et al. (2023) · Cureus · doi:10.7759/cureus.43725 · Cited by 5
Pathogenesis of Antiphospholipid Antibody Syndrome
Giles, I., Cohen, H., & Ioannou, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00024-4 · Cited by 5
Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome
Martins, F., & Campos, T. M. L. (2021) · TH Open · doi:10.1055/s-0041-1736289 · Cited by 6
Systemic Lupus Erythematosus
Petri, M., Abuav, R., Boumpas, D. T., Goldblatt, F., Isenberg, D. A., Anhalt, G. J., Werth, V. P., & Looney, R. J. (2009) · Springer eBooks · doi:10.1007/978-1-84800-934-9_13 · Cited by 5
Comparison of lung perfusion scintigraphic findings in pulmonary thromboembolism in systemic lupus erythematosus, SLE plus antiphospholipid syndrome, and primary antiphospholipid syndrome
AUNG, W., MURATA, Y., Ishida, R., et al. (2000) · Nuclear Medicine Communications · doi:10.1097/00006231-200003000-00015 · Cited by 5
“The results of our study corroborate those of a previous study on the occurrence of pulmonary thromboembolism in SLE patients with aPL antibodies [12].”
Result
Coronary heart disease (CHD) in lupus: round up the usual suspects?
Bruce, I. N. (2004) · Lupus · doi:10.1191/0961203304lu1066ed · Cited by 5
Diagnostic biologique du syndrome des antiphospholipides
Darnige, L. (2005) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2005.08.014 · Cited by 10
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository (‘Registry’)
Thaler, J., Parides, M., ANDRADE, D. C. O. D., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.10.019 · Cited by 4
Long-term prognosis of vascular access in hemodialysis patients with systemic lupus erythematosus: a retrospective cohort study
Chen, F.-Y., Chen, C.-F., Tan, A. C., Chan, C.-H., Chen, F., Liu, W., Chen, T., Ou, S., Li, S., Tsai, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92005-5 · Cited by 4
HEMATOLOGY: COAGULATION PROBLEMS
Shapiro, S. S., & Spurgeon, S. E. F. (2004) · Elsevier eBooks · doi:10.1016/b978-012433901-9/50045-4 · Cited by 4
Risque thromboembolique veineux au cours des affections médicales aiguës. Partie 2 : situations à risque en milieu ambulatoire, en milieu médical hospitalier et en médecine interne
Jeune, S. L., Pistorius, M.-A., Planchon, B., & Pottier, P. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.023 · Cited by 4
Thrombotic Manifestations in the Antiphospholipid Syndrome
Ordi‐Ros, J., Selva-O’Callaghan, A., & Vilardell, M. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50018-8 · Cited by 4
Testing strategies for diagnosing lupus anticoagulant: Decision analysis
Segal, J. B., Lehmann, H. P., Petri, M., Mueller, L., & Kickler, T. S. (2002) · American Journal of Hematology · doi:10.1002/ajh.10115 · Cited by 4
15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report
Zuily, S., Barbhaiya, M., Costenbader, K. H., & Erkan, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_15 · Cited by 4
Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis
Willis, R., Cohen, H., Giles, I., Knight, J. S., Krilis, S. A., Rahman, A., & de Groot, P. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_5 · Cited by 5
Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome
Caraiola, S., Jurcuț, C., Dima, A., et al. (2018) · Revista română de medicină de laborator · doi:10.2478/rrlm-2018-0009 · Cited by 4
“Of these, LAC seems to carry the greater risk for either arterial or venous thrombotic event [11].”
Background
Antiphospholipids in cutaneous vasculitis
Gantcheva, M., & Angelova, I. (1999) · Clinics in Dermatology · doi:10.1016/s0738-081x(99)00067-x · Cited by 4
Female patients with systemic lupus erythematosus (SLE)-associated antiphospholipid syndrome (APS) have a lower ovarian reserve than either primary APS or SLE patients
Xu, X., Wang, H., Cai, S., et al. (2024) · Journal of Laboratory Medicine · doi:10.1515/labmed-2023-0126 · Cited by 3

Authors: Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G.
Affiliations: Service de Medicine H., Nancy University Hospital, Nancy, France
Université de Lorraine (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
ORCID: Guillemin, F.
de Maistre, E.
Lecompte, T.
Venue: Lupus
Publisher: SAGE Publications
Published: 1997-06
Volume: 6
Issue: 5
Pages: 467-473
ISSN: 0961-2033 (ISSN-L)
1477-0962
DOI: 10.1177/096120339700600510
OpenAlex: W2080975717
Semantic Scholar: c31dc580c59a1ad743aa46934306445622100694
Cited by: 285
References: 29
Citations by year: 2026: 3 · 2025: 3 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 5
FWCI: 1.89
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Lupus (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords: venous thrombosis, antiphospholipid antibodies, systemic lupus erythematosus, lupus anticoagulant, anticardiolipin antibodies, deep vein thrombosis, pulmonary embolism, recurrent venous thrombosis, thrombosis risk
MeSH terms: Autoimmune Diseases, Disease Susceptibility, Epidemiologic Methods, Humans, Lupus Erythematosus, Systemic, Risk, Thrombophlebitis, Comorbidity, Odds Ratio, Single-Blind Method, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks